1. Laboratory safety during assisted reproduction in patients with blood-borne viruses
- Author
-
Corinne Liesnard, Yvon Englert, Carole Gilling-Smith, Serena Emiliani, and Paula Almeida
- Subjects
Male ,medicine.medical_specialty ,Safety Management ,Hepatitis, Viral, Human ,Reproductive Techniques, Assisted ,media_common.quotation_subject ,Human immunodeficiency virus (HIV) ,Fertility ,HIV Infections ,medicine.disease_cause ,Pregnancy ,HIV Seropositivity ,medicine ,Blood-Borne Pathogens ,Humans ,Intensive care medicine ,media_common ,Hepatitis ,Cryopreservation ,biology ,business.industry ,Rehabilitation ,Obstetrics and Gynecology ,Hepatitis C ,medicine.disease ,biology.organism_classification ,Spermatozoa ,Infectious Disease Transmission, Vertical ,Reproductive Medicine ,Virus Diseases ,Immunology ,Lentivirus ,Female ,Laboratory safety ,Reproduction ,business ,Laboratories - Abstract
For couples where one or both partners are infected with human immunodeficiency virus or hepatitis C, the doors to receiving fertility care are opening as a result of better antiviral medication, better long-term prognosis and consequent changes in attitude. In line with this, fertility centres electing to treat couples with blood-borne viral (BBV) infection need to re-examine their policies and procedures to ensure the safety of their staff and both non-infected and infected patients during assisted reproduction treatments. At a time when the European Tissue Directive aims to introduce quality standards for assisted reproduction throughout Europe, we highlight the risks involved when treating patients with known BBV infections and argue that safety cannot be met with any certainty unless samples from such patients are handled within a separate high security laboratory or laboratory area, technically adapted to ensure minimal cross-contamination risk to uninfected gametes and embryos.
- Published
- 2005